Cytokeratin 19 and galectin‐3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules

Beesley, Matthew F.; McLaren, K M

doi:10.1046/j.1365-2559.2002.01442.x

Cited by 126 publications

(150 citation statements)

References 33 publications

(86 reference statements)

Supporting

Mentioning

128

Contrasting

Unclassified

Order By: Relevance

“…Interestingly, GAL3 expression was seen in six of seven neoplasms of uncertain malignant potential, which may support the proposal made by some investigators that GAL3 is a marker of early malignant transformation and minimally invasive carcinoma. 11,22 Our results suggest the 'indeterminate or borderline' nature of these lesions. Although these markers fail to classify these tumors as clearly malignant or benign, they may help in selecting tumors for prolonged follow-up in order to determine their true biologic nature.…”

Section: Discussionmentioning

confidence: 60%

“…Other investigators have also reported GAL3 expression in benign thyroid lesions by various techniques including reverse transcription-PCR. 22,[29][30][31][32] The second problem with GAL3 was that seven carcinomas (8%) were false negative.…”

Section: Discussionmentioning

confidence: 99%

“…KRT19 encodes cytokeratin-19 (CK19), a cytoskeletal protein that is significantly increased in papillary thyroid carcinoma, and has been reported to be helpful in distinguishing it from other benign and malignant thyroid nodules. 5,[19][20][21][22][23] HBME1, a monoclonal antibody generated against a suspension of malignant epithelial mesothelioma cells, reacts with the microvillous surface protein of mesothelial cells. We included HBME1 because its expression has been reported in papillary and follicular thyroid carcinoma but not in normal thyroid cells.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors

et al. 2005

View full text Add to dashboard Cite

The diagnosis of thyroid tumors is critical for clinical management; however, tumors with follicular architecture often present problems. We evaluated the diagnostic use of the protein expression of four genes that were found to be upregulated in papillary thyroid carcinoma compared to normal thyroid (LGALS3, FN1, CITED1 and KRT19), and of the mesothelial cell surface protein recognized by monoclonal antibody HBME1 in thyroid tumors. Tissues from 85 carcinomas (67 papillary, six follicular, eight Hü rthle cell and four anaplastic) and 21 adenomas were evaluated by immunohistochemistry for the expression of these gene protein products, for example, galectin-3 (GAL3), fibronectin-1 (FN1), CITED1, cytokeratin-19 (CK19) and HBME1. Non-neoplastic thyroids (29 adenomatous and 14 thyrotoxic hyperplasia, and 59 normal) were also studied. The expression of all five proteins was significantly associated with malignancy, and highly specific (Z90%) for carcinoma compared to adenoma. GAL3, FN1 and/or HBME1 expression was seen in 100% of carcinomas (85/85) and in 24% of adenomas (5/21). Coexpression of multiple proteins was seen in 95% of carcinomas and only 5% of adenomas (Po0.0001). Coexpression of FN1 and GAL3 (FN1 þ GAL3 þ , 70/85) or FN1 and HBME1 (FN1 þ HBME1 þ , 53/85) was restricted to carcinomas, while their concurrent absence (FN1ÀGAL3À or FN1ÀHBME1À, 18/21 adenoma) was highly specific (96%) for benign lesions. Among non-neoplastic thyroids, adenomatous hyperplasia frequently expressed GAL3 (n ¼ 16), CK19 (n ¼ 9) and CITED1 (n ¼ 7), but the expression was predominantly focal in contrast to the diffuse expression in carcinomas. An immunohistochemical panel consisting of GAL3, FN1 and HBME1 may be useful in the diagnosis of follicular cell-derived thyroid tumors.

show abstract

Section: Discussionmentioning

confidence: 60%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors

et al. 2005

View full text Add to dashboard Cite

show abstract

“…Recent interest has focused on the expression of galectin-3 and thyroid transcription factor-1 (TTF-1). Studies demonstrated the positivities of galectin-3 in 100% of papillary carcinomas, 90 -100% of follicular carcinomas, 50 -80% of medullary carcinomas, 0 -33% of follicular adenomas and 0 -38% of nodular goitres (Beesley et al, 2002). Thyroid transcription factor-1 also expressed 100% of differentiated follicular tumours including follicular adenoma, follicular carcinoma and papillary carcinoma, but only 25% of undifferentiated carcinoma of the thyroid (Katoh et al, 2000).…”

Section: Discussionmentioning

confidence: 99%

Overexpression of leucocyte common antigen (LAR) P-subunit in thyroid carcinomas

et al. 2003

View full text Add to dashboard Cite

Protein tyrosine phosphatase (PTPase) dephosphorylation and protein tyrosine kinase (PTKs) phosphorylation of key signal transduction proteins may be regulated by extracellular signals, making PTPases important in the regulation of cell proliferation. Leucocyte common antigen (LAR), a receptor-like PTPase, consists of E-subunit, containing the cell adhesion molecule-like receptor region, and P-subunit specific for a short segment of the extracellular region, the transmembrane peptide, and two cytoplasmic PTPase domains. We produced a monoclonal antibody against the LAR P-subunit for immunohistochemical screening of LAR expression in normal and tumourous tissues. Gliomas and gastric, colorectal, lung, breast and prostate cancers showed weak and relatively infrequent expression. Intense and diffuse expression, however, was detected in 95% (227 out of 239) of thyroid carcinomas, but only 12% (22 out of 128) of adenomas and no cases of benign thyroid disease were immunopositive. In contrast to broad staining in carcinomas, LAR expression in thyroid adenomas was often found in small focal or locally invasive areas. Western blot analysis similarly detected LAR P-subunit protein in thyroid carcinomas, but not in normal tissues. We believe this to be the first demonstration of LAR overexpression in thyroid carcinoma and may help to elucidate the role of PTPases in the development of malignancy.

show abstract

“…Chose 10 high power visual fields randomly under microscope, count positive cell numbers in 100 tumor cells in each one filed, and than the average value was represented as the expression intensity of Ki67. According to Beesley (Beesley, 2002) classify method, immunoreactivity (no staining or weak staining) was scored as negative, immunoreactivity (staining less DOI:http://dx.doi.org/10.7314/APJCP.2015.16.4…”

Section: Immunohistochemical Evaluationmentioning

confidence: 99%

Expression of Ki67 in Papillary Thyroid Microcarcinoma and its Clinical Significance

Zhang¹,

Jiang²,

Lü³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Purpose: To investigate the expression of Ki67 protein in papillary thyroid microcarcinoma(PTMC), and to analyze its clinical significance. Materials and Methods: Ki67 protein expression was evaluated in the tissues of 108 human PTMC and 50 other benign papillary hyperplasia of thyroid specimens using immunohistochemistry. Results: The expression intensity of Ki67 in PTMC and benign papillary hyperplasia of thyroid specimens were 1.45±1.83% and 0.46±0.46%.The positive expression rates were 46.3% and 14%. There were significant differences between these two groups (p<0.01). There was no significant variation of the expression intensity and positive expression rates of Ki67 in PTMC with gender, age, position of the tumor and the level of TSH pre-operation (p>0.05), but these parameters varied with tumor size, invasion by membrane and cervical lymph node metastasis (p<0.05 or p<0.01). Conclusions: The expression of Ki67 in PTMC was related to tumor size, invasion by membrane and cervical lymph node metastasis, and could be the important indicator for judging clinical progress and estimating prognosis.

show abstract

Cytokeratin 19 and galectin‐3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules

Cited by 126 publications

References 33 publications

Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors

Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors

Overexpression of leucocyte common antigen (LAR) P-subunit in thyroid carcinomas

Expression of Ki67 in Papillary Thyroid Microcarcinoma and its Clinical Significance

Contact Info

Product

Resources

About